DOCKET

Paper No. 56

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT AND TRIAL APPEAL BOARD

APOTEX INC., Petitioner,

v.

UCB BIOPHARMA SPRL, Patent Owner.

> Case IPR2019-00400 Patent 8,633,194 B2

Record of Oral Hearing Held Virtually: Wednesday, April 22, 2020

Before ROBERT A. POLLOCK, RYAN H. FLAX, and KRISTIL. R. SAWERT, *Administrative Patent Judges*.

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Case IPR2019-00400 Patent 8,633,194 B2

APPEARANCES:

ON BEHALF OF THE PETITIONER:

JITENDRAMALIK, ESQUIRE ALISSA PACCHIOLI, ESQUIRE JOSEPH JANUSZ, ESQUIRE KATTEN MUCHIN ROSENMAN LLP 550 S. Tryon Street, Suite 2900 Charlotte, NC 28202

LANCE SODERSTROM, ESQUIRE KATTEN MUCHIN ROSENMAN LLP 575 Madison Avenue, Suite 14 New York, NY 10022

ON BEHALF OF THE PATENT OWNER:

ROBERT COUNIHAN, ESQUIRE ERICA SUTTER, ESQUIRE FENWICK & WEST LLP 801 California Street Mountain View, CA 94041

JAMES TRAINOR, ESQUIRE FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010

DOCKE

The above-entitled matter came on for hearing on Wednesday, April 22, 2020, commencing at 1:00 p.m. EST, by video/by telephone.

2 JUDGE POLLOCK: Good afternoon. This is	S
3 the final hearing in IPR2019-00400 regarding	
4 Claims 1 through 11 of U.S. Patent Number	
5 8,633,194 B2.	
6 Petitioner is Apotex, Incorporated.	
7 Patent owner is UCB Biopharma Sprl.	
8 This hearing is open to the public, and a	
9 full transcript of the hearing	
10 will be made part of the record.	
11 I'm Judge Pollock. With me are Judges	
12 Flax and Sawert.	
13 Counsel for Petitioner Apotex, would you	
14 kindly identify yourself and any colleagues on the	;
15 line.	
16 MR. MALIK: Good afternoon, your Honors.	
17 This is Jitendra Malik, counsel, Apotex. With	
18 me with me are Lance Soderstrom, Joe Janusz,	
19 Alissa Pacchioli, and also Dipu Mukherjee and the	e
20 client, Olga Kalinina.	
21 JUDGE POLLOCK: Good afternoon, all.	
22 Counsel for Patent Owner UCB, would you	
23 kindly identify yourself and any colleagues with	
24 you.	
25 MR. COUNIHAN: Yes. Good afternoon, yo	ur

2

Case IPR2019-00400 Patent 8,633,194 B2

1	Honors. This is Robert Counihan of Fenwick &
2	West. With me on the phone from Fenwick are James
3	Trainor and Erica Sutter, and from UCB are
4	Stephane Drouin and Amanda Blanchard.
5	JUDGE POLLOCK: Good afternoon. I
6	understand the parties have set forth motions to
7	exclude, motions to seal, and lodged objections to
8	each other's demonstratives. We will not rule on
9	the motions today but will address them in our
10	final written decision to the extent necessary.
11	We also remind the parties that the
12	demonstratives are not evidence. We,
13	nevertheless, take your objections under
14	advisement.
15	As set forth in the scheduling order of
16	March 11th, 2020, each side has 60 minutes to
17	present its case. My colleagues and I will do our
18	best to keep track of time, but we suggest that
19	the parties do the same.
20	You are welcome but not required to argue
21	your motions and objections during your allotted
22	time. It may, however, be helpful if the parties
23	would touch on Dr. Niazi's credibility as was
24	raised in the motions practice.
25	There also seems to be some uncertainty
26	regarding whether the liquid pharmaceutical

Case IPR2019-00400 Patent 8,633,194 B2

composition of Claim 1 encompasses single and
multi-use parenteral formulations which, being liquid,
might appear reasonable.
It would be helpful if the parties explain
their understanding of the scope of Claim 1 and
the weight we should give to the prior art
directed to non-oral non-liquid formulations.
That said, counsel for petitioner, would you like to
reserve any time for rebuttal?
MR. MALIK: Yes, your Honor, 30 minutes.
JUDGE POLLOCK: Counsel for patent owner,
you may have the last word today if you wish.
Would you like to reserve any of your time?
MR. COUNIHAN: Yes, I'd like to reserve
15 minutes, your Honor.
JUDGE POLLOCK: Very good. We are looking
forward to your presentations today, but I would
like to cover a few more things before we begin.
On behalf of the board, we thank you for
your flexibility in participating in this all-
video hearing. Given that this is a departure
from our typical practice, I would first emphasize
that our primary concern is your right to be
heard. If at any time during the proceeding you
encounter technical or other difficulties that you
feel fundamentally undermine your ability to

5

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.